State Specialty Directory
Medical Oncology in TX
Federal CMS data for 411 medical oncology providers across TX. Includes Medicare utilization, Open Payments industry funding, and PECOS enrollment status.
411
Providers
Median industry payments
$3,483
411
Medical Oncology Providers
in TX
$3,483
Median Industry Payments
per provider (2018–2024)
453
Median Medicare Services
fee-for-service claims
How to read this directory: Providers are listed by Medicare service volume, which reflects only
Medicare fee-for-service patients (typically 65+). This does not represent total practice volume.
Industry payments span multiple years and payment types — they are legal and do not indicate wrongdoing.
Medical Oncology includes multiple subspecialties with different practice patterns.
Learn more →
Showing top 50 of 411 providers, ranked by Medicare service volume. Search by city to narrow results.
Medical Oncology Providers — TX
NPPES · Open Payments · Medicare| Provider | City | Medicare Volume | Beneficiaries* | Top Procedure | Industry Payments | Payment Type | Coverage |
|---|---|---|---|---|---|---|---|
| CHOKSI, ASIT MD | The Woodlands | 383,841 | 1,396 | Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram | $5,239 (2018-2024) | Gift (97%) | Very High |
| CHALLAGALLA, JAGATHI M.D. | Wichita Falls | 372,508 | 9,387 | Iron infusion (Feraheme) | $91,549 (2018-2024) | Consulting (77%) | Very High |
| KOCS, DARREN MD | Round Rock | 366,526 | 6,847 | Iron sucrose injection (Venofer) | $267 (2018-2024) | Education (74%) | Very High |
| ULRICH, BRIAN M.D. | Wichita Falls | 327,937 | 3,538 | Iron infusion (Feraheme) | $4,921 (2018-2024) | Food & Beverage (97%) | Very High |
| PRAKASH, SUCHARU MD | Paris | 231,844 | 6,995 | Iron infusion (Feraheme) | $131,454 (2018-2024) | Consulting (83%) | Very High |
| DRENGLER, RONALD M.D. | San Antonio | 223,535 | 3,891 | Oxaliplatin chemotherapy injection | $7,743 (2018-2024) | Food & Beverage (96%) | Very High |
| WILCOX, CELESTE MD, PHD | Paris | 207,951 | 5,230 | Iron infusion (Feraheme) | $597 (2018-2024) | Food & Beverage (89%) | Very High |
| RAO, JAYASREE M.D. | San Antonio | 204,265 | 2,410 | Injection, filgrastim-ayow, biosimilar, (releuko), 1 microgram | $15,672 (2018-2024) | Food & Beverage (95%) | Very High |
| MELNYK, ANTON MD,FACP | Abilene | 193,993 | 6,588 | Iron infusion (Feraheme) | $18,117 (2018-2024) | Consulting (55%) | Very High |
| HELLERSTEDT, BETH M.D. | Round Rock | 161,989 | 6,928 | Iron sucrose injection (Venofer) | $482 (2018-2024) | Food & Beverage (53%) | Very High |
| TEBCHERANY, DINA MD | Austin | 159,618 | 4,036 | Pembrolizumab injection (Keytruda) | $304 (2021-2024) | Food & Beverage (61%) | Very High |
| KIRKPATRICK, HASKELL MD | Dallas | 158,235 | 4,784 | Darbepoetin injection (Aranesp) for anemia | $1,333 (2018-2024) | Food & Beverage (99%) | Very High |
| GREGORY, THOMAS M.D. | Tyler | 140,067 | 4,911 | Iron infusion (Feraheme) | $2,757 (2018-2024) | Food & Beverage (96%) | Very High |
| MAREK, BILLIE MD | Mcallen | 134,172 | 3,028 | Iron infusion (Feraheme) | $649 (2018-2024) | Food & Beverage (94%) | Very High |
| KARIPPOT, ASHA MD | Plano | 134,142 | 4,258 | Iron infusion (Feraheme) | $4,592 (2018-2024) | Food & Beverage (73%) | Very High |
| SAKRUTI, SUSMITA M.D | Denison | 129,293 | 5,002 | Iron infusion (Feraheme) | $9,607 (2018-2024) | Food & Beverage (80%) | Very High |
| AGARWAL, ASHWANI M.D. | Dallas | 128,584 | 2,171 | Iron sucrose injection (Venofer) | $287,998 (2018-2024) | Consulting (62%) | Very High |
| SHARMA, NEERAJ MD | Longview | 126,783 | 4,820 | Iron infusion (Feraheme) | $3,969 (2018-2024) | Honoraria (61%) | Very High |
| TRILLO, GERARDO M.D. | Frisco | 119,293 | 3,579 | Iron infusion (Feraheme) | $2,801 (2018-2024) | Food & Beverage (88%) | Very High |
| RICHARDS, DONALD MD | Tyler | 116,825 | 4,648 | Iron infusion (Feraheme) | $40,917 (2018-2024) | Consulting (62%) | Very High |
| MANALO, YVONNE MD | Corpus Christi | 116,793 | 829 | Filgrastim injection (Nivestym) for white blood cells | $17,513 (2018-2024) | Food & Beverage (94%) | Very High |
| ZAHOOR, HARIS MD | Houston | 112,003 | 4,889 | Iron infusion (Injectafer) | $12,007 (2018-2024) | Consulting (48%) | Very High |
| AKHTAR, SYED M.D. | Beaumont | 111,847 | 3,305 | Iron infusion (Feraheme) | $2,026 (2018-2024) | Food & Beverage (77%) | Very High |
| O'SHAUGHNESSY, JOYCE MD | Dallas | 111,460 | 3,907 | Pembrolizumab injection (Keytruda) | $1,378,319 (2018-2024) | Consulting (77%) | Very High |
| KALLA, HARI MD | Abilene | 108,466 | 5,911 | Iron infusion (Feraheme) | $2,626 (2018-2024) | Food & Beverage (99%) | Very High |
| GUNUGANTI, VIJAY M.D. | San Antonio | 105,773 | 3,378 | Nivolumab injection (Opdivo) | $1,449,397 (2018-2024) | Consulting (94%) | Very High |
| CHAWLA, JANE MD | Austin | 105,551 | 3,646 | Anti-nausea injection (fosaprepitant) | $524 (2018-2024) | Food & Beverage (77%) | Very High |
| ANDERSON, JADE M.D. | Amarillo | 105,132 | 3,268 | Iron infusion (Feraheme) | $534 (2018-2024) | Food & Beverage (66%) | Very High |
| BARRINGTON, REBECCA M.D. | Kerrville | 104,730 | 6,682 | Iron infusion (Feraheme) | $1,682 (2018-2024) | Food & Beverage (81%) | Very High |
| BERRYMAN, ROBERT M.D. | Dallas | 104,583 | 2,896 | Immune globulin infusion (Octagam) | $162,583 (2018-2024) | Consulting (62%) | Very High |
| SCHACHNER, JAY MD | Beaumont | 98,693 | 2,862 | Iron infusion (Feraheme) | $1,276 (2018-2024) | Food & Beverage (64%) | Very High |
| LATTANZI, MICHAEL | Austin | 98,260 | 2,689 | Darbepoetin injection (Aranesp) for anemia | $155,982 (2022-2024) | Consulting (78%) | Very High |
| KHANDELWAL, PANKAJ MD | Odessa | 94,639 | 2,996 | Iron sucrose injection (Venofer) | $83 (2018-2021) | Education (100%) | Very High |
| BHURIWALA, MURTAZA MD | Tomball | 93,901 | 972 | Iron infusion (Injectafer) | $58,254 (2018-2024) | Consulting (49%) | Very High |
| HEAVEN, RALPH M.D. | Abilene | 88,761 | 4,132 | Iron infusion (Feraheme) | $3,158 (2018-2024) | Food & Beverage (93%) | Very High |
| PATEL, MRUGESH MD | Bedford | 88,238 | 2,430 | Paclitaxel chemotherapy injection | $2,424 (2018-2024) | Consulting (47%) | Very High |
| BARTOSH, NICOLE D.O. | Granbury | 80,538 | 1,553 | Iron infusion (Injectafer) | $1,155 (2018-2024) | Food & Beverage (96%) | Very High |
| MCINTYRE, KRISTI MD | Dallas | 75,158 | 3,457 | Pembrolizumab injection (Keytruda) | $3,188 (2018-2024) | Consulting (65%) | Very High |
| NADLER, ERIC MD | Dallas | 73,958 | 3,274 | Pembrolizumab injection (Keytruda) | $1,582,808 (2018-2024) | Consulting (84%) | Very High |
| JONES, MONTE MD | Mckinney | 73,688 | 2,662 | Iron sucrose injection (Venofer) | $3,029 (2018-2024) | Food & Beverage (98%) | Very High |
| PARK, MICHAEL MD | Lewisville | 73,465 | 2,872 | Iron sucrose injection (Venofer) | $5,166 (2018-2024) | Consulting (62%) | Very High |
| SHUMWAY, NATHAN D.O., FACP | San Antonio | 72,895 | 3,728 | Iron infusion (Feraheme) | $6,186 (2018-2024) | Food & Beverage (50%) | Very High |
| STONE, SCOTT MD | Plano | 72,697 | 3,731 | Iron sucrose injection (Venofer) | $17,457 (2018-2024) | Consulting (46%) | Very High |
| DRAKSHARAM, PADMA MD | Abilene | 71,280 | 3,839 | Iron infusion (Feraheme) | $4,367 (2018-2024) | Food & Beverage (86%) | Very High |
| ALBINO, MIGUEL MD | Austin | 71,035 | 2,079 | Anti-nausea injection (fosaprepitant) | $298,314 (2018-2024) | Consulting (92%) | Very High |
| WALBERG, MARK M.D. | Dallas | 69,909 | 1,757 | Pembrolizumab injection (Keytruda) | $581 (2020-2024) | Food & Beverage (98%) | Very High |
| FRASE, LARRY M.D. | Longview | 65,445 | 3,912 | Pembrolizumab injection (Keytruda) | $3,633 (2018-2024) | Food & Beverage (53%) | Very High |
| SANDERA, MARISA M.D. | Boerne | 63,891 | 1,680 | Iron infusion (Injectafer) | $16,274 (2018-2024) | Food & Beverage (100%) | Very High |
| COCHRAN, ERNEST M.D. | Paris | 63,607 | 2,584 | Iron infusion (Feraheme) | $882 (2019-2024) | Food & Beverage (84%) | Very High |
| KASPER, MICHAEL MD | Austin | 62,447 | 4,186 | Pembrolizumab injection (Keytruda) | $132 (2020-2024) | Education (59%) | Very High |
Note: Medical Oncology encompasses multiple subspecialties with different practice patterns.
Differences in payment amounts and procedure volumes may reflect subspecialty focus
rather than practice quality. Consider viewing individual profiles for full context.